Trial · NCT04562766
Participant flow80
How many started, completed or left each group, period by period.
1 to 20 of 80
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| DB Period (Weeks 1 to 24) | STARTED | DB Period: Adults: Placebo | 69 | |
| DB Period (Weeks 1 to 24) | STARTED | DB Period: Adults: Rilzabrutinib 400 mg BID | 133 | |
| DB Period (Weeks 1 to 24) | STARTED | DB Period: Adolescent: Placebo | 12 | |
| DB Period (Weeks 1 to 24) | STARTED | DB Period: Adolescent: Rilzabrutinib 400 mg BID | 18 | |
| DB Period (Weeks 1 to 24) | STARTED | OL Period: Adults: Rilzabrutinib 400 mg BID | 0 | |
| DB Period (Weeks 1 to 24) | STARTED | OL Period: Adolescent: Rilzabrutinib 400 mg BID | 0 | |
| DB Period (Weeks 1 to 24) | STARTED | LTE Period: Adults: Rilzabrutinib 400 mg BID | 0 | |
| DB Period (Weeks 1 to 24) | STARTED | LTE Period: Adolescent: Rilzabrutinib 400 mg BID | 0 | |
| DB Period (Weeks 1 to 24) | Completed 12-week DB Period | DB Period: Adults: Placebo | 66 | |
| DB Period (Weeks 1 to 24) | Completed 12-week DB Period | DB Period: Adults: Rilzabrutinib 400 mg BID | 121 | |
| DB Period (Weeks 1 to 24) | Completed 12-week DB Period | DB Period: Adolescent: Placebo | 12 | |
| DB Period (Weeks 1 to 24) | Completed 12-week DB Period | DB Period: Adolescent: Rilzabrutinib 400 mg BID | 18 | |
| DB Period (Weeks 1 to 24) | Completed 12-week DB Period | OL Period: Adults: Rilzabrutinib 400 mg BID | 0 | |
| DB Period (Weeks 1 to 24) | Completed 12-week DB Period | OL Period: Adolescent: Rilzabrutinib 400 mg BID | 0 | |
| DB Period (Weeks 1 to 24) | Completed 12-week DB Period | LTE Period: Adults: Rilzabrutinib 400 mg BID | 0 | |
| DB Period (Weeks 1 to 24) | Completed 12-week DB Period | LTE Period: Adolescent: Rilzabrutinib 400 mg BID | 0 | |
| DB Period (Weeks 1 to 24) | COMPLETED | DB Period: Adults: Placebo | 10 | |
| DB Period (Weeks 1 to 24) | COMPLETED | DB Period: Adults: Rilzabrutinib 400 mg BID | 62 | |
| DB Period (Weeks 1 to 24) | COMPLETED | DB Period: Adolescent: Placebo | 2 | |
| DB Period (Weeks 1 to 24) | COMPLETED | DB Period: Adolescent: Rilzabrutinib 400 mg BID | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04562766/flow